Replimune Group, Inc. (NASDAQ:REPL) Receives $4.75 Consensus PT from Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has been given an average rating of “Reduce” by the ten ratings firms that are covering the company, Marketbeat reports. Four analysts have rated the stock with a sell rating and six have assigned a hold rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $4.75.

REPL has been the topic of a number of analyst reports. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 price target (down from $11.00) on shares of Replimune Group in a research note on Monday, April 13th. Wedbush reaffirmed a “neutral” rating and issued a $2.00 price target (down from $19.00) on shares of Replimune Group in a research note on Monday, April 13th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of Replimune Group in a research note on Monday, April 13th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $2.00 price target (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. Finally, Wall Street Zen cut Replimune Group from a “sell” rating to a “strong sell” rating in a research note on Saturday, April 25th.

Replimune Group Stock Performance

Shares of NASDAQ REPL opened at $5.16 on Friday. The stock has a market cap of $426.06 million, a price-to-earnings ratio of -1.50 and a beta of 0.12. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33. Replimune Group has a 1-year low of $1.50 and a 1-year high of $13.24. The stock’s 50-day moving average is $5.16 and its 200 day moving average is $7.42.

Insider Buying and Selling

In other Replimune Group news, insider Christopher Sarchi sold 6,500 shares of Replimune Group stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $8.01, for a total value of $52,065.00. Following the transaction, the insider directly owned 151,588 shares of the company’s stock, valued at $1,214,219.88. The trade was a 4.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Replimune Group

Large investors have recently bought and sold shares of the stock. International Assets Investment Management LLC purchased a new position in Replimune Group in the 4th quarter worth approximately $29,000. Russell Investments Group Ltd. grew its position in shares of Replimune Group by 3,638.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after buying an additional 7,569 shares during the last quarter. CWM LLC grew its position in shares of Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after buying an additional 2,886 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of Replimune Group by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after buying an additional 6,873 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Replimune Group in the 2nd quarter worth approximately $69,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.